PD-1/L1

Delve into the world of PD-1/L1 in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on PD-1/L1 to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

AnnJi Advances AJ201 into Pivotal Phase 3 ROMA‑KD Trial – The Only Investigational Therapy for SBMA in Late‑Stage Development Worldwide
CompanyDrug

AnnJi Advances AJ201 into Pivotal Phase 3 ROMA‑KD Trial – The Only Investigational Therapy for SBMA in Late‑Stage Development Worldwide

AnnJi Pharmaceutical Co., Ltd. (TPEx: 7754), a clinical‑stage drug development company focused on innovative small molecules, announced that it is proceeding with the U.S. portion of its pivotal Phase 3…

Asymchem's Tianjin Macromolecule Site Passes First FDA Pre‑Approval Inspection – EIR Issued for Commercial API Facility

Asymchem’s Tianjin Macromolecule Site Passes First FDA Pre‑Approval Inspection – EIR Issued for Commercial API Facility

Pfizer's Oral Ritlecitinib Meets Primary Endpoints in Phase III Nonsegmental Vitiligo Trials – Largest‑Ever Oral Systemic Program Clears Path for Global Filings

Pfizer’s Oral Ritlecitinib Meets Primary Endpoints in Phase III Nonsegmental Vitiligo Trials – Largest‑Ever Oral Systemic Program Clears Path for Global Filings

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Ascletis Pharma’s PD-L1 Inhibitor ASC61 Gains NMPA IND Approval

CompanyDrug

Akeso Biopharma’s AK112 Receives Two New Breakthrough Therapy Designations

Company

EQRx Shifts Strategy Amid FDA Feedback on China-Sourced Data

CompanyDrug

CStone’s PD-L1 Inhibitor Sugemalimab Achieves Primary Endpoint in Gastric Cancer Study

CompanyDrug

Merck’s Keytruda Receives 10th Indication Approval in China for TNBC

CompanyDrug

Qilu Pharma’s QL1706 Shows Promise in Phase II Cervical Cancer Study

CompanyDrug

Abbisko Enrolls First Patient in Phase II Study for ABSK091 in Urothelial Carcinoma

CompanyDrug

Akeso Biopharma Completes Enrollment for AK112 Phase III Study

Show More